← Leaderboards
Mike Robertson
Lovelace Biomedical Research Institute
$2,262,947
Attributed
$2,262,947
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $2M · FY2023–24$2M$1.5M$1M$500K$0
'23
'24
Funding mix
By agency
NIH$2,262,947 · 1
By mechanism
N01$2,262,947 · 1
Top collaborators
No co-investigators on record.
Most similar at Lovelace Biomedical Research Institute
Same institution · by research overlap
- Jane Lindborg$16,749
Others in their field
Other Rising Stars on “Biodistribution”
- Yicheng Wang · Immunova Therapeutics, Llc$4,000,000
- Javier Caravaca · University Of California, San Francisco$3,728,080
- C.k. Osborne · Leidos Biomedical Research, Inc.$3,516,733
- Alireza Hassani Najafabadi · Terasaki Institute For Biomedical Innovation$3,065,252
- Christopher W Peterson · Fred Hutchinson Cancer Center$3,006,188
- Jasdave Chahal · Tiba Biotech, Llc$2,898,030
Research focus
BiodistributionEfficacy EvaluationContractorEvaluationMethod DevelopmentProgramsTransgene ExpressionSafetyGene TherapyGovernmentLeadDependovirusNational Center For Advancing Translational SciencesCollaborationsTherapeutics For Rare And Neglected DiseasesMouse ModelEfficacy StudyDesignMeasurementGenotypeBiometryGenerationsKetotic HyperglycinemiaBehavioral Assay
Grant awards (5)
CHARACTERIZATION OF SPONTANEOUS OSTEOGENESIS AFTER SURGICAL SEGMENTAL BONE DEFECT IN A LARGE ANIMAL$192,050
N01 · FY2024 · DA · contact PI
EFFICACY AND SAFETY EVALUATION OF A LEAD GENE THERAPY CANDIDATE IN PROPIONIC ACIDEMIA (PA) DISEASE MOUSE MODELS AND BIOANALYTICAL ASSAY METHODS DEVELOPMENT.$51,059
N01 · FY2024 · DA · contact PI
BIOANALYTICAL SUPPORTS FOR A GLP TOX/BIODISTRIBUTION STUDY IN MINI-PIGS$44,201
N01 · FY2024 · DA · contact PI
EFFICACY AND SAFETY EVALUATION OF LEAD GENE THERAPY CANDIDATE IN NEUROMUSCULAR JUNCTION (NMJ) DISEASE MOUSE MODELS AND BIOANALYTICAL ASSAY METHODS DEVELOPMENT$1,595,870
N01 · FY2023 · DA · contact PI
EFFICACY AND SAFETY EVALUATION OF A LEAD GENE THERAPY CANDIDATE IN PROPIONIC ACIDEMIA (PA) DISEASE MOUSE MODELS AND BIOANALYTICAL ASSAY METHODS DEVELOPMENT.$379,767
N01 · FY2023 · DA · contact PI